回顾性研究洛铂依托泊苷化疗治疗小细胞肺癌的疗效和毒性。
Retrospective study of the efficacy and toxicity of lobaplatin-etoposide chemotherapy in small cell lung cancer.
机构信息
Department of Oncology, Tianjin Medical University General Hospital, Tianjin, China.
出版信息
Thorac Cancer. 2019 Feb;10(2):226-233. doi: 10.1111/1759-7714.12936. Epub 2019 Jan 2.
BACKGROUND
A retrospective study was conducted to assess the efficacy and toxicity of lobaplatin-etoposide (EL) chemotherapy for small cell lung cancer (SCLC).
METHODS
The clinical data of 50 patients treated in our department from May 2014 to March 2018 were obtained. Untreated patients with SCLC administered LBP intravenously (IV) at 30 mg/m on day 1 and etoposide IV at 100 mg/m on days 1, 2, and 3 were enrolled. The treatment was cycled every 21 days.
RESULTS
The median overall and progression-free survival rates of the 50 patients were 11.67 (range: 7.30-16.04) and 6.8 (range: 5.25-8.35) months, respectively, with an overall response rate of 66% and a disease control rate of 90%. The most frequent drug-related adverse effects were leukopenia and neutropenia, and no grade 3/4 hepatotoxicity or nephrotoxicity was observed.
CONCLUSION
These results indicate that LBP-containing chemotherapy is effective and tolerable for SCLC in terms of response and survival.
背景
本研究回顾性分析洛铂联合依托泊苷（EL）方案治疗小细胞肺癌（SCLC）的疗效和毒性。
方法
收集 2014 年 5 月至 2018 年 3 月本科收治的未经治疗的 SCLC 患者 50 例，采用洛铂 30 mg/m2 静脉滴注（IV），第 1 天；依托泊苷 100 mg/m2 IV，第 1、2、3 天。每 21 天为 1 个周期。
结果
50 例患者的中位总生存时间和无进展生存时间分别为 11.67（7.3016.04）个月和 6.80（5.258.35）个月，总缓解率为 66%，疾病控制率为 90%。最常见的药物相关不良反应为白细胞减少和中性粒细胞减少，未观察到 3/4 级肝毒性或肾毒性。
结论
洛铂联合依托泊苷方案治疗 SCLC 有效且可耐受，在缓解率和生存方面有较好的疗效。
Zotero 插件